DENTSPLY SIRONA Inc.XRAY
DENTSPLY SIRONA Inc. Segments Disclosure
SEGMENT AND GEOGRAPHIC INFORMATION
The Company has four operating segments, organized primarily by product, which are also the Company’s reportable segments. These are (i) Connected Technology Solutions, (ii) Essential Dental Solutions, (iii) Orthodontic and Implant Solutions, and (iv) Wellspect Healthcare. They generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight with the exception of Wellspect Healthcare, which has a more discrete market and regulatory environment specific to the medical device industry. These operating segments, which also form the Company’s reportable segments, are identified in accordance with how the Company’s chief operating decision maker (“CODM”) regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources. The Company’s CODM is the Chief Executive Officer.
The CODM assesses performance of the segments based on the net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain unallocated corporate costs, interest expense, net, other (income) expense, net, goodwill and intangible asset impairments, restructuring and other costs, amortization of intangible assets, other acquisition costs, and depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations. Asset and other balance sheet information is not reported to the CODM.
The CODM uses both net sales and segment adjusted operating income for each segment during development of the annual operating plan and the regular forecasting process. Additionally, the CODM considers budget-to-actual variances for these measures on a quarterly basis as well as segment-specific forecasting when making decisions about the allocation of operating and capital resources to each segment.
A description of the products and services provided within each of the Company’s four reportable segments is provided below.
Connected Technology Solutions
This segment includes the design, manufacture and sales of the Company’s dental technology and equipment products. These products include the Equipment & Instruments and CAD/CAM product categories.
Equipment & Instruments
The Equipment & Instruments product category consists of dental equipment products such as imaging equipment, motorized dental handpieces, treatment centers, and other instruments for dental practitioners and specialists. Imaging equipment serves as a key point of entry to the Company’s digital workflow offerings and consists of a broad range of diagnostic imaging systems for 2D or 3D, panoramic, and intraoral applications, as well as cone-beam computed tomography systems (“CBCT”). Treatment centers comprise a broad range of products from basic dental chairs to sophisticated chair-based units with integrated diagnostic, hygienic and ergonomic functionalities, as well as specialist centers used in preventive treatment and for training purposes. This product group also includes other lab equipment, such as amalgamators, mixing machines and porcelain furnaces.
CAD/CAM
Dental CAD/CAM technologies are products designed for dental professionals to support numerous digital workflows for procedures such as dental restorations through integrations with DS Core, our cloud-based platform. This product category includes intraoral scanners, 3-D printers, mills, and certain software and services, as well as a full-chairside economical restoration of esthetic ceramic dentistry offering called CEREC, which enables dentists to practice same-day or single visit dentistry.
Essential Dental Solutions
This segment includes the development, manufacture and sales of the Company’s value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Offerings in this segment also include specialized treatment products including products used in the creation of dental appliances.
Essential Dental Solutions products are designed to operate in an integrated system to provide solutions for high-tech dental procedures. The endodontic products include motorized endodontic handpieces, files, sealers, irrigation needles and other tools or single-use solutions which support root canal procedures. The restorative products include curing light systems, dental ceramics, composites, and other materials used in prosthetic restorations, including crowns and veneers.
The preventive products include small equipment, such as dental diagnostic systems and ultrasonic scalers and polishers, as well as other dental supplies including dental anesthetics, prophylaxis paste, dental sealants, and impression materials.
Orthodontic and Implant Solutions
This segment includes the design, manufacture, and sales of the Company’s various digital implant systems and innovative dental implant products, digital dentures, and digital orthodontic solutions. Offerings in this segment also include application of our digital services and technology, including those provided by DS Core, our cloud-based platform.
Orthodontics
The Orthodontics product category includes the SureSmile brand, a comprehensive digital treatment planning and orthodontic appliance solution. The cloud-based software is used to prescribe SureSmile clear aligners, robotically bent wires, and digital indirect bonding trays. The SureSmile Simulator uses intraoral scanners and our DS Core platform to create a 3D visualization of potential patient outcomes. The category also includes whitening kits and retainers. The Orthodontics product category previously included a direct-to-consumer clear aligner product marketed as Byte, which was no longer offered to new patients after October 24, 2024. The Company continues to provide support to Byte clear aligner patients in treatment, provided they meet certain criteria.
Implants & Prosthetics
The Implants & Prosthetics product category includes a portfolio of innovative dental implant products, supported by the Company’s digital workflow for implant solutions, digital dentures, crown and bridge products, bone regenerative and restorative solutions, treatment planning software and educational programs. The Implants & Prosthetics product category is supported by key technologies including custom abutments, advanced tapered immediate load screws and regenerative bone growth factor. Offerings in this category also include dental prosthetics such as artificial teeth.
Wellspect Healthcare
This segment includes the design, manufacture, and sales of the Company’s innovative continence care solutions for both urinary and bowel management. Wellspect Healthcare is a leading global manufacturer and provider of innovative medical devices, including catheters to help people suffering from urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation, which combine a high degree of user convenience, clinical effectiveness and connectivity into one smart system.
The Company’s segment financial information was as follows:
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2025 | |||||||||||||||||||||||||||||||||||
| (in millions) | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total | ||||||||||||||||||||||||||||||
| Net sales | 1,036 | 1,469 | 850 | 325 | 3,680 | ||||||||||||||||||||||||||||||
Adjusted cost of products sold (a) | 614 | 555 | 392 | 131 | |||||||||||||||||||||||||||||||
Adjusted selling expenses (b) | 221 | 301 | 222 | 55 | |||||||||||||||||||||||||||||||
Adjusted G&A expenses (b) | 81 | 76 | 80 | 27 | |||||||||||||||||||||||||||||||
Adjusted R&D expenses (c) | 68 | 23 | 48 | 10 | |||||||||||||||||||||||||||||||
| Segment adjusted operating income | 52 | 514 | 108 | 102 | 776 | ||||||||||||||||||||||||||||||
| Reconciling items (income) expense: | |||||||||||||||||||||||||||||||||||
Unallocated corporate costs (d) | 311 | ||||||||||||||||||||||||||||||||||
| Interest expense, net | 88 | ||||||||||||||||||||||||||||||||||
| Other (income) expense, net | (24) | ||||||||||||||||||||||||||||||||||
| Goodwill and intangible asset impairments | 650 | ||||||||||||||||||||||||||||||||||
| Restructuring and other costs | 24 | ||||||||||||||||||||||||||||||||||
| Amortization of intangibles | 211 | ||||||||||||||||||||||||||||||||||
| Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations | 2 | ||||||||||||||||||||||||||||||||||
| Loss before income taxes | (486) | ||||||||||||||||||||||||||||||||||
(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.
(b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs.
(c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs.
(d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment.
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2024 | |||||||||||||||||||||||||||||||||||
| (in millions) | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total | ||||||||||||||||||||||||||||||
| Net sales | 1,062 | 1,454 | 973 | 304 | 3,793 | ||||||||||||||||||||||||||||||
Adjusted cost of products sold (a) | 602 | 565 | 407 | 117 | |||||||||||||||||||||||||||||||
Adjusted selling expenses (b) | 242 | 313 | 301 | 52 | |||||||||||||||||||||||||||||||
Adjusted G&A expenses (b) | 74 | 74 | 133 | 27 | |||||||||||||||||||||||||||||||
Adjusted R&D expenses (c) | 74 | 23 | 52 | 10 | |||||||||||||||||||||||||||||||
| Segment adjusted operating income | 70 | 479 | 80 | 98 | 727 | ||||||||||||||||||||||||||||||
| Reconciling items (income) expense: | |||||||||||||||||||||||||||||||||||
Unallocated corporate costs (d) | 320 | ||||||||||||||||||||||||||||||||||
| Interest expense, net | 69 | ||||||||||||||||||||||||||||||||||
| Other (income) expense, net | (12) | ||||||||||||||||||||||||||||||||||
| Goodwill and intangible asset impairments | 1,014 | ||||||||||||||||||||||||||||||||||
| Restructuring and other costs | 53 | ||||||||||||||||||||||||||||||||||
| Amortization of intangibles | 216 | ||||||||||||||||||||||||||||||||||
| Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations | 3 | ||||||||||||||||||||||||||||||||||
| Loss before income taxes | (936) | ||||||||||||||||||||||||||||||||||
(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.
(b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs.
(c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs.
(d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment.
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2023 | |||||||||||||||||||||||||||||||||||
| (in millions) | Connected Technology Solutions | Essential Dental Solutions | Orthodontic and Implant Solutions | Wellspect Healthcare | Total | ||||||||||||||||||||||||||||||
| Net sales | 1,169 | 1,468 | 1,040 | 288 | 3,965 | ||||||||||||||||||||||||||||||
Adjusted cost of products sold (a) | 645 | 560 | 402 | 114 | |||||||||||||||||||||||||||||||
Adjusted selling expenses (b) | 264 | 313 | 305 | 51 | |||||||||||||||||||||||||||||||
Adjusted G&A expenses (b) | 77 | 94 | 119 | 25 | |||||||||||||||||||||||||||||||
Adjusted R&D expenses (c) | 82 | 23 | 58 | 11 | |||||||||||||||||||||||||||||||
| Segment adjusted operating income | 101 | 478 | 156 | 87 | 822 | ||||||||||||||||||||||||||||||
| Reconciling items (income) expense: | |||||||||||||||||||||||||||||||||||
Unallocated corporate costs (d) | 319 | ||||||||||||||||||||||||||||||||||
| Interest expense, net | 81 | ||||||||||||||||||||||||||||||||||
| Other (income) expense, net | 9 | ||||||||||||||||||||||||||||||||||
| Goodwill and intangible asset impairments | 307 | ||||||||||||||||||||||||||||||||||
| Restructuring and other costs | 67 | ||||||||||||||||||||||||||||||||||
| Amortization of intangibles | 211 | ||||||||||||||||||||||||||||||||||
| Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations | 3 | ||||||||||||||||||||||||||||||||||
| Loss before income taxes | (175) | ||||||||||||||||||||||||||||||||||
(a) Adjusted cost of products sold represents expenses adjusted to exclude intangible amortization expense, step-up depreciation expense, and other restructuring costs.
(b) Adjusted selling and adjusted G&A expenses represent expenses adjusted to exclude intangible amortization expense, other acquisition costs, step-up depreciation expense, and other restructuring costs.
(c) Adjusted R&D expenses represent expenses adjusted to exclude other restructuring costs.
(d) Unallocated corporate costs consist of general corporate expenses including corporate headcount costs, depreciation and amortization, certain professional service fees, and other operating costs which are not assigned to a specific segment.
| Depreciation and Amortization | Year Ended December 31, | |||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
| Connected Technology Solutions | $ | 186 | $ | 175 | $ | 176 | ||||||||||||||
| Essential Dental Solutions | 34 | 35 | 33 | |||||||||||||||||
| Orthodontic and Implant Solutions | 90 | 98 | 97 | |||||||||||||||||
| Wellspect Healthcare | 18 | 19 | 18 | |||||||||||||||||
All Other (a) | 24 | 22 | 19 | |||||||||||||||||
| Total | $ | 352 | $ | 349 | $ | 343 | ||||||||||||||
(a) Includes unallocated corporate costs for depreciation and amortization
Geographic Information
The following tables set forth information about the Company’s significant operations by geographic areas, for the years ended December 31, 2025, 2024, and 2023. Net sales reported below represent revenues from external customers in those respective countries based on the destination of shipments.
| Year Ended December 31, | ||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
| Net sales | ||||||||||||||||||||
| United States | $ | 1,182 | $ | 1,348 | $ | 1,437 | ||||||||||||||
| Germany | 422 | 410 | 431 | |||||||||||||||||
| Other Foreign | 2,076 | 2,035 | 2,097 | |||||||||||||||||
| Total net sales | $ | 3,680 | $ | 3,793 | $ | 3,965 | ||||||||||||||
Property, plant and equipment, net, represents those long-lived assets held by the operating businesses located in the respective geographic areas.
| Year Ended December 31, | ||||||||||||||||||||
| (in millions) | 2025 | 2024 | 2023 | |||||||||||||||||
| Property, plant, and equipment, net | ||||||||||||||||||||
| United States | $ | 206 | $ | 210 | $ | 194 | ||||||||||||||
| Germany | 247 | 230 | 260 | |||||||||||||||||
| Sweden | 124 | 101 | 105 | |||||||||||||||||
| Other Foreign | 284 | 225 | 241 | |||||||||||||||||
| Total property, plant, and equipment, net | $ | 861 | $ | 766 | $ | 800 | ||||||||||||||
Product and Customer Information
For information on the Company’s net sales by product category comprising each of the reportable segments, see Note 2, Revenue Recognition.
Concentration Risk
Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2025 were as follows:
| Year Ended December 31, | ||||||||||||||
| 2025 | ||||||||||||||
| % of net sales | % of accounts receivable | |||||||||||||
| Henry Schein, Inc. | 13 | % | Less than 10% | |||||||||||
| Patterson Companies, Inc. | Less than 10% | 11 | % | |||||||||||
For the year ended December 31, 2024, no customer accounted for 10% or more of consolidated net sales or consolidated accounts receivable.
Customers that accounted for 10% or more of net sales or accounts receivable for the year ended December 31, 2023 were as follows:
| Year Ended December 31, | ||||||||||||||
| 2023 | ||||||||||||||
| % of net sales | % of accounts receivable | |||||||||||||
| Henry Schein, Inc. | 14 | % | 11 | % | ||||||||||
| Patterson Companies, Inc. | Less than 10% | 10 | % | |||||||||||
Free Sentinel
Track for freeWant the next DENTSPLY SIRONA Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment DENTSPLY SIRONA Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.